Short answer
GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor Presentation intended for recurring use with investors and stakeholders.
GLAUKOS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor Presentation intended for recurring use with investors and stakeholders
- Exhibit 99.1 provides the substantive company information for investor review
- Materials available on Glaukos’ investor-relations website for ongoing access
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation highlights 30% 2025 topline growth and $627.5 million 2026 revenue guidance midpoint
- iDose TR FDA-approved for re-administration in January 2026, strengthening recurring procedural-pharmaceutical potential
- Epioxa commercially launched in March 2026, expanding Glaukos into epithelium-on keratoconus treatment
- Pipeline spans 13 disclosed programs across glaucoma, cornea, eyelid delivery and retina
- Balance sheet shows $281 million cash and equivalents with no debt as of March 31, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GLAUKOS Corp 8-K filings
Get the next GKOS 8-K as it lands
Follow GKOS for push alerts, or ask the research agent what this filing means.